Cyclosporin H; 纯度: 99.17%
Cyclosporin H 是 FPR-1 (甲酰肽受体 1) 的选择性强效抑制剂。Cyclosporin H 是一种病毒转导 (viral transduction) 增强剂,可使人脐带血来源的造血干细胞和祖细胞 (HSPCs) 中慢病毒转导增强 10 倍。Cyclosporin H 与雷帕霉素 (HY-10219) 或前列腺素 E2 (HY-101952) 联合使用时表现出累加效应。Cyclosporin H 缺乏 Cyclosporin A 具有的免疫抑制活性。
Cyclosporin H Chemical Structure
CAS No. : 83602-39-5
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
5 mg | ¥3800 | In-stock | |
10 mg | ¥6500 | In-stock | |
50 mg | ; | 询价 | ; |
100 mg | ; | 询价 | ; |
* Please select Quantity before adding items.
Cyclosporin H 相关产品
bull;相关化合物库:
- Bioactive Compound Library Plus
- Anti-Infection Compound Library
- Immunology/Inflammation Compound Library
- Peptide Library
生物活性 |
Cyclosporin H is a selective and potent inhibitor of FPR-1 (formyl peptide receptor 1). Cyclosporin H, a viral transduction enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). Cyclosporin H displays an additive effect when combined with Rapamycin (HY-10219) or Prostaglandin E2 (HY-101952). Cyclosporin H lacks immunosuppressant activity of Cyclosporin A. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
The cyclic undecapeptide, cyclosporin H, is a potent inhibitor of formyl-Met-Leu-Phe (FMLP)-induced superoxide anion (O2-) formation in human neutrophils. Cyclosporin H inhibits FMLP binding in HL-60 membranes with a Ki of 0.1 μM. Cyclosporin H inhibits activation by FMLP of high affinity GTPase (the enzymatic activity of alpha-subunits of heterotrimeric regulatory guanine nucleotide-binding proteins) in HL-60 membranes with a Ki of 0.79 μM. Cyclosporin H inhibits the stimulatory effects of FMLP on cytosolic Ca2+ concentration ([Ca2+]i), O2- formation, and beta-glucuronidase release with Ki values of 0.08, 0.24, and 0.45 μM, respectively[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
Cyclosporin H (5 mg/kg; i.p.; before LPS or HCl challenge) attenuats lung injury induced by LPS or HCl (a lung injurymodel)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
1202.61 |
||||||||||||||||
Formula |
C62H111N11O12 |
||||||||||||||||
CAS 号 |
83602-39-5 |
||||||||||||||||
Sequence |
Cyclo[{Abu}-{Sar}-{N(Me)Leu}-Val-{N(Me)Leu}-Ala-{d-Ala}-{N(Me)Leu}-{N(Me)Leu}-{d-N(Me)Val}-{N(Me)Bmt(E)}] |
||||||||||||||||
Sequence Shortening |
Cyclo[{Abu}-{Sar}-{N(Me)Leu}-V-{N(Me)Leu}-A-{d-Ala}-{N(Me)Leu}-{N(Me)Leu}-{d-N(Me)Val}-{N(Me)Bmt(E)}] |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:;
DMSO : 100 mg/mL (83.15 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|